You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Anti-Diubiquitin antibody (ab43773)

CodeSizePriceAbpointsAvailability
    
Add to basket
 

  • -

  •   
  •   
  •   

  •  

  •  
  •  

  •  

  •  
Updating...

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »

Overview

Product name

Anti-Diubiquitin antibody

Description

Mouse polyclonal to Diubiquitin

Tested applications

WBmore details

Cross reactivity

Reacts with

Human

Immunogen

Recombinant fusion protein tagged (Human)

Properties

Form

Liquid

Storage instructions

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

Storage buffer

Preservative: None
Constituents: 50% Glycerol, Whole serum

Purity

Whole antiserum

Primary antibody notes

This antibody was raised by a genetic immunization technique. Genetic immunization can be used to generate antibodies by directly delivering antigen-coding DNA into the animal, rather than injecting a protein or peptide (Tang et al.PubMed: 1545867; Chambers and Johnston PubMed 12910245; Barry and Johnston PubMed: 9234514). The animal's cells produce the protein, which stimulates the animal's immune system to produce antibodies against that particular protein. A vector coding for a partial fusion protein was used for genetic immunisation of a mouse and the resulting serum was tested in Western blot against an E.coli lysate containing that partial fusion protein. Genetic immunization offers enormous advantages over the traditional protein-based immunization method. DNA is faster, cheaper and easier to produce and can be produced by standard techniques readily amenable to automation. Furthermore, the antibodies generated by genetic immunization are usually of superior quality with regard to specificity, affinity and recognizing the native protein.

Clonality

Polyclonal

Isotype

IgG

Research areas

Immunology >> Secreted Molecules >> Other secreted molecules
Cell Biology >> Proteolysis / Ubiquitin >> Proteasome / Ubiquitin >> Ub-like Proteins
Microbiology >> Protein >> Human Protein >> Defensin

Applications

Show applications key

Our Abpromise guarantee covers the use of ab43773 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • WB

     

Application notes

WB: 1/1000. Predicted molecular weight: 18 kDa.
This antibody has been tested in Western blot against an E.coli lysate containing the partial recombinant fusion protein used as an immunogen. We have no data on detection of endogenous protein.

Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.

Target

Function

Ubiquitin-like protein modifier which can be covalently attached to target protein and subsequently leads to their degradation by the 26S proteasome, in a NUB1L-dependent manner. Probably functions as a survival factor. Conjugation ability activated by UBA6. Promotes the expression of the proteasome subunit beta type-9 (PSMB9/LMP2). Regulates TNF-alpha-induced and LPS-mediated activation of the central mediator of innate immunity NF-kappa-B by promoting TNF-alpha-mediated proteasomal degradation of ubiquitinated-I-kappa-B-alpha. Required for TNF-alpha-induced p65 nuclear translocation in renal tubular epithelial cells (RTECs). May be involved in dendritic cell (DC) maturation, the process by which immature dendritic cells differentiate into fully competent antigen-presenting cells that initiate T cell responses. Mediates mitotic non-disjunction and chromosome instability, in long-term in vitro culture and cancers, by abbreviating mitotic phase and impairing the kinetochore localization of MAD2L1 during the prometaphase stage of the cell cycle. May be involved in the formation of aggresomes when proteasome is saturated or impaired. Mediates apoptosis in a caspase-dependent manner, especially in renal epithelium and tubular cells during renal diseases such as polycystic kidney disease and Human immunodeficiency virus (HIV)-associated nephropathy (HIVAN).

Tissue specificity

Constitutively expressed in mature dendritic cells and B cells. Mostly expressed in the reticuloendothelial system (e.g. thymus, spleen), the gastrointestinal system, kidney, lung and prostate gland.

Sequence similarities

Contains 2 ubiquitin-like domains.

Post-translational
modifications

Can be acetylated.

Cellular localization

Nucleus. Cytoplasm. Accumulates in aggresomes under proteasome inhibition conditions.

Target information above from: UniProt accessionO15205 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • Diubiquitin antibody
  • FAT10 antibody
  • UBD 3 antibody
  • Ubd antibody
  • UBD_HUMAN antibody
  • Ubiquitin D antibody
  • Ubiquitin like protein FAT10 antibody
  • Ubiquitin-like protein FAT10 antibody
see all

Database links

References for Anti-Diubiquitin antibody (ab43773)

ab43773 has not yet been referenced specifically in any publications.

Publishing research using ab43773? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"